<li>apomorphine<p>quetiapine decreases effects of apomorphine by pharmacodynamic antagonism. Avoid or Use Alternate Drug.</p></li><li>atazanavir<p>atazanavir increases levels of quetiapine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Consider alternative anti-HCV therapy to avoid increases in quetiapine exposures; if coadministration is necessary, reduce quetiapine dose to 1/6th of current dose and monitor for quetiapine associated adverse reactions; refer to quetiapine prescribing information for recommendations on adverse reaction monitoring.</p></li><li>bromocriptine<p>quetiapine decreases effects of bromocriptine by pharmacodynamic antagonism. Avoid or Use Alternate Drug.</p></li><li>cabergoline<p>quetiapine decreases effects of cabergoline by pharmacodynamic antagonism. Contraindicated.</p></li><li>carbamazepine<p>carbamazepine will decrease the level or effect of quetiapine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>cimetidine<p>cimetidine will increase the level or effect of quetiapine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>clarithromycin<p>clarithromycin will increase the level or effect of quetiapine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>cobicistat<p>cobicistat increases levels of quetiapine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration with quetiapine. If coadministration is necessary, reduce quetiapine dose to one-sixth of the current dose.</p></li><li>dabrafenib<p>dabrafenib will decrease the level or effect of quetiapine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>dopamine<p>quetiapine decreases effects of dopamine by pharmacodynamic antagonism. Contraindicated.</p></li><li>elvitegravir/cobicistat/emtricitabine/tenofovir df<p>elvitegravir/cobicistat/emtricitabine/tenofovir df increases levels of quetiapine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration with quetiapine. If coadministration is necessary, reduce quetiapine dose to one-sixth of the current dose.</p></li><li>erythromycin base<p>erythromycin base will increase the level or effect of quetiapine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>erythromycin ethylsuccinate<p>erythromycin ethylsuccinate will increase the level or effect of quetiapine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>erythromycin lactobionate<p>erythromycin lactobionate will increase the level or effect of quetiapine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>erythromycin stearate<p>erythromycin stearate will increase the level or effect of quetiapine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>histrelin<p>histrelin increases toxicity of quetiapine by QTc interval. Avoid or Use Alternate Drug. Increases risk of torsades de pointes.</p></li><li>hydroxyzine<p>hydroxyzine increases toxicity of quetiapine by QTc interval. Avoid or Use Alternate Drug. Increases risk of torsades de pointes.</p></li><li>idelalisib<p>idelalisib will increase the level or effect of quetiapine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Idelalisib is a strong CYP3A inhibitor; avoid coadministration with sensitive CYP3A substrates</p></li><li>itraconazole<p>itraconazole will increase the level or effect of quetiapine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>ivacaftor<p>ivacaftor increases levels of quetiapine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Ivacaftor and its M1 metabolite has the potential to inhibit CYP3A4, may significantly increase systemic exposure to 3A4 substrates.</p></li><li>ketoconazole<p>ketoconazole will increase the level or effect of quetiapine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>levodopa<p>quetiapine decreases effects of levodopa by pharmacodynamic antagonism. Avoid or Use Alternate Drug.</p></li><li>lisuride<p>quetiapine decreases effects of lisuride by pharmacodynamic antagonism. Contraindicated.</p></li><li>mefloquine<p>mefloquine increases toxicity of quetiapine by QTc interval. Avoid or Use Alternate Drug. Mefloquine may enhance the QTc prolonging effect of high risk QTc prolonging agents.</p></li><li>methyldopa<p>quetiapine decreases effects of methyldopa by pharmacodynamic antagonism. Contraindicated.</p></li><li>nafarelin<p>nafarelin increases toxicity of quetiapine by QTc interval. Avoid or Use Alternate Drug. Increases risk of torsades de pointes.</p></li><li>nefazodone<p>nefazodone will increase the level or effect of quetiapine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>ombitasvir/paritaprevir/ritonavir<p>ombitasvir/paritaprevir/ritonavir will increase the level or effect of quetiapine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Consider alternative anti-HCV therapy to avoid increased quetiapine exposure with strong CYP3A4 inhibitors. If coadministration is necessary, reduce the quetiapine dose to 1/6th of the current/recommended dose and monitor for quetiapine-associated adverse reactions.</p></li><li>ombitasvir/paritaprevir/ritonavir &amp; dasabuvir<p>ombitasvir/paritaprevir/ritonavir &amp; dasabuvir will increase the level or effect of quetiapine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Consider alternative anti-HCV therapy to avoid increases in quetiapine exposures; if coadministration necessary, reduce quetiapine dose to 1/6th of current dose and monitor for quetiapine associated adverse reactions; refer to quetiapine prescribing information for recommendations on adverse reaction monitoring </p></li><li>ondansetron<p>quetiapine and ondansetron both increase  QTc interval. Avoid or Use Alternate Drug.  Avoid with congenital long QT syndrome; ECG monitoring recommended with concomitant medications that prolong QT interval, electrolyte abnormalities, CHF, or bradyarrhythmias.</p></li><li>panobinostat<p>quetiapine and panobinostat both increase  QTc interval. Avoid or Use Alternate Drug. Panobinostat is known to significantly prolong QT interval. Panobinostat prescribing information states use with drugs known to prolong QTc is not recommended.</p></li><li>pimavanserin<p>pimavanserin and quetiapine both increase  QTc interval. Avoid or Use Alternate Drug. Coadministration may increase the risk of QT prolongation and cardiac arrhythmia.</p></li><li>pramipexole<p>quetiapine decreases effects of pramipexole by pharmacodynamic antagonism. Contraindicated.</p></li><li>ribociclib<p>ribociclib and quetiapine both increase  QTc interval. Avoid or Use Alternate Drug.</p></li><li>rifabutin<p>rifabutin will decrease the level or effect of quetiapine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>rifampin<p>rifampin will decrease the level or effect of quetiapine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>ropinirole<p>quetiapine decreases effects of ropinirole by pharmacodynamic antagonism. Contraindicated.</p></li><li>sodium oxybate<p>quetiapine, sodium oxybate.
Either increases effects of the other by pharmacodynamic synergism. Contraindicated. Additive CNS depression.</p></li><li>st john's wort<p>st john's wort will decrease the level or effect of quetiapine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>triptorelin<p>triptorelin increases toxicity of quetiapine by QTc interval. Avoid or Use Alternate Drug. Increases risk of torsades de pointes.</p></li><li>umeclidinium bromide/vilanterol inhaled<p>quetiapine increases toxicity of umeclidinium bromide/vilanterol inhaled by QTc interval. Avoid or Use Alternate Drug. Exercise extreme caution when vilanterol coadministered with drugs that prolong QTc interval; adrenergic agonist effects on the cardiovascular system may be potentiated.</p></li><li>vemurafenib<p>vemurafenib and quetiapine both increase  QTc interval. Avoid or Use Alternate Drug. Concomitant use of vemurafenib with drugs that  prolong QT interval is not recommended.</p></li><li>vilanterol/fluticasone furoate inhaled<p>quetiapine increases toxicity of vilanterol/fluticasone furoate inhaled by QTc interval. Avoid or Use Alternate Drug. Exercise extreme caution when vilanterol coadministered with drugs that prolong QTc interval; adrenergic agonist effects on the cardiovascular system may be potentiated.</p></li>